The Medicines Co (MDCO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

8 SYLVAN WAY PARSIPPANY, NJ 07054

Operates as a pharmaceutical company that specializes in acute care hospital products. Its first acute care hospital product, Angiomax (bivalirudin), is a direct thrombin inhibitor used as an anticoagulant in patients undergoing coronary angioplasty.

View SEC Filings from MDCO instead.

View recent insider trading info

 
The Medicines Co Chart by YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Check out our reporting and analysis

Funds Holding MDCO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MDCO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HUGIN ROBERT J

  • Director
 10,335 2020-05-20 0

KINGSLEY STUART A

  • Director
 0 2020-05-20 0

SCHLESINGER SARAH J.

  • Director
 58,082 2020-04-24 1

SBLENDORIO GLENN PRESIDENT AND CEO

  • Officer
  • Director
 225,061 2020-04-01 0

SAVAGE ROBERT G.

0 2020-04-01 0

GERMANO GENO J

  • Director
 0 2020-03-10 1

MEANWELL CLIVE CHIEF INNOVATION OFFICER

  • Officer
  • Director
 0 2020-01-06 3

RODIN STEPHEN M EVP AND GENERAL COUNSEL

  • Officer
 0 2020-01-06 4

DENNER ALEXANDER J

  • Director
 0 2020-01-06 2

PANAYIOTOPOULOS PARIS

  • Director
 0 2020-01-06 1

VISIOLI CHRISTOPHER CHIEF FINANCIAL OFFICER

  • Officer
 0 2020-01-06 2

TIMNEY MARK CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
 0 2020-01-06 3

WIJNGAARD PETER CHIEF DEVELOPMENT OFFICER

  • Officer
 0 2020-01-06 3

ESHELMAN FREDRIC N

  • Director
 0 2019-11-19 0

KELLY JOHN C.

  • Director
 0 2019-09-26 1

KELLEY JOHN P

  • Director
 0 2019-06-19 0

COX CHRISTOPHER T EVP & CHIEF CORP. DEV. OFFICER

  • Officer
 392,942 2019-03-04 0

SPIGELMAN MELVIN K

  • Director
 48,305 2018-08-15 0

KESSLER ARMIN M

  • Director
 138,493 2018-05-10 0

WYATT ELIZABETH H S

  • Director
 60,633 2018-03-22 0

CROUSE WILLIAM

  • Director
 53,133 2018-03-21 0

O'CONNOR WILLIAM BERNARD CHIEF FINANCIAL OFFICER

  • Officer
 21,882 2018-03-02 0

FRAZIER JEFF EVP, CHIEF HUMAN STRATEGY

  • Officer
 34,350 2018-03-02 0

FURSE BRENT

0 2018-01-05 0

SHIGETA HIROAKI

  • Director
 26,784 2017-05-25 0

KUSIAK VICTORIA EVP, CHIEF INTEGRITY OFFICER

  • Officer
 3,519 2014-03-03 0

HEIMAN CORNELIS EVP, CHIEF INNOVATION OFFICER

  • Officer
 11,457 2014-03-03 0

ANTINORI PAUL MICHAEL SR. VP & GENERAL COUNSEL

  • Officer
 No longer subject to file 2014-02-25 0

ROHRBACKER LESLIE C VP, CHIEF HUMAN STRATEGY OFFIC

  • Officer
 13,628 2012-02-21 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD PARTNERS, LP

DEERFIELD MANAGEMENT CO /NY

DEERFIELD INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUP
 No longer subject to file 2011-04-04 0

JOHNSON T SCOTT

  • Director
 No longer subject to file 2009-07-21 0

WATSON PACICCO KELLI SENIOR VICE PRESIDENT

  • Officer
 2,211 2009-02-20 0

NEWBERRY CATHARINE S SENIOR VICE PRESIDENT

  • Officer
 No longer subject to file 2009-01-26 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions

Elevate your investments